The present invention provides a therapy for treating loss of GABA-mediated pre-synaptic inhibition after spinal injury. The therapeutic regimen includes spinal segment-specific upregulation of GAD65 (glutamate decarboxylase) and VGAT (vesicular GABA transporter) to modulate chronic spasticity in patients after spinal traumatic or ischemic injury.

The present invention provides a therapy for treating loss of GABA-mediated pre-synaptic inhibition after spinal injury. The therapeutic regimen includes spinal segment-specific upregulation of GAD65 (glutamate decarboxylase) and VGAT (vesicular GABA transporter) to modulate chronic spasticity in patients after spinal traumatic or ischemic injury.

A process for preparing an organo-iodinated compound, comprising the following steps: a) acylating 2,4,6-triiodo-5-aminoisophthalic acid of formula (A) below: ##STR00001## to obtain an intermediate compound Ya; b) chlorinating the intermediate compound Ya to obtain an organo-iodinated intermediate compound Yb; c) amidating the organo-iodinated intermediate compound Yb to obtain an intermediate compound Yc; and d) deprotecting the intermediate compound Yc, the steps a), b), c) and d) being carried out without isolation of at least one intermediate compound chosen from Ya and Yc.

A process for preparing an organo-iodinated compound, comprising the following steps: a) acylating 2,4,6-triiodo-5-aminoisophthalic acid of formula (A) below: ##STR00001## to obtain an intermediate compound Ya; b) chlorinating the intermediate compound Ya to obtain an organo-iodinated intermediate compound Yb; c) amidating the organo-iodinated intermediate compound Yb to obtain an intermediate compound Yc; and d) deprotecting the intermediate compound Yc, the steps a), b), c) and d) being carried out without isolation of at least one intermediate compound chosen from Ya and Yc.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.

Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.

The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.